公开(公告)号：US10913792B2

公开(公告)日：2021-02-09

申请号：US15880726

申请日：2018-01-26

Applicant: MORPHOSYS AG

Inventor： Stefan Hartle ,  Stephane Leclair ,  Amgad Shebl ,  Stefan Steidl ,  Bodo Brocks ,  Daniela Della Ducata ,  Kai Rosport

IPC: C07K16/24 ,  A61K31/519 ,  A61K39/395 ,  A61K39/00

Abstract: The present invention provides anti-GM-CSF antibodies for use in the treatment of rheumatoid arthritis. Anti-GM-CSF antibodies, in particular MOR103, are administered to patients suffering from rheumatoid arthritis at dosages that are beneficial in a clinical setting.

公开(公告)号：US20180230208A1

公开(公告)日：2018-08-16

申请号：US15880726

申请日：2018-01-26

Applicant: Morphosys Ag

Inventor： Stefan Hartle ,  Stephane Leclair ,  Amgad Shebl ,  Stefan Steidl

IPC: C07K16/24 ,  A61K31/519 ,  A61K39/395 ,  A61K39/00

Abstract: The present invention provides anti-GM-CSF antibodies for use in the treatment of rheumatoid arthritis. Anti-GM-CSF antibodies, in particular MOR103, are administered to patients suffering from rheumatoid arthritis at dosages that are beneficial in a clinical setting.

公开(公告)号：US20150246969A1

公开(公告)日：2015-09-03

申请号：US14429996

申请日：2013-09-19

Applicant: MORPHOSYS AG

Inventor： Stefan Hartle ,  Stephane Leclair ,  Amgad Shebl ,  Stefan Steidl

IPC: C07K16/24 ,  A61K31/519 ,  A61K39/395

Abstract: The present invention provides anti-GM-CSF antibodies for use in the treatment of rheumatoid arthritis. Anti-GM-CSF antibodies, in particular MOR103, are administered to patients suffering from rheumatoid arthritis at dosages that are beneficial in a clinical setting.

Abstract translation: 本发明提供用于治疗类风湿性关节炎的抗GM-CSF抗体。 将抗GM-CSF抗体，特别是MOR103，以有利于临床环境的剂量施用于患有类风湿性关节炎的患者。